Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

References

• Anderson GP. Formoterol, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145–2160
   PubMed Web of Science ®Google Scholar
• Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur Respir J 1994; 7: 569–578
   PubMed Web of Science ®Google Scholar
• Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 41: 115–137
   Google Scholar
• Bartow RA, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55: 303–322
   PubMed Web of Science ®Google Scholar
• Derom E, Pauwels RA. Time-course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992; 47: 30–33
   PubMed Web of Science ®Google Scholar
• Wallin A, Sandström T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611–614
   PubMed Web of Science ®Google Scholar
• Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102: 535–538
   PubMedGoogle Scholar
• Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PG. Bronchodilator effect of inhaled formoterol vs. salbutamol over 12 hours. Chest 1990; 97: 590–594
   PubMedGoogle Scholar
• Clauzel AM, Molimard M, Le Gros V, Lepère E, Febvre N, Michel FB. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. J Invest Allergol Clin Immunol 1998; 8: 265–270
   PubMedGoogle Scholar
• FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till D, Brambilla R. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999; 103: 427–435
   PubMed Web of Science ®Google Scholar
• Thomson NC, Angus R, Quebe-Fehling E, Brambilla R. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998; 92: 562–567
   PubMedGoogle Scholar
• Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo- controlled study comparing formoterol dry powder inhaler with albuterol metered dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19–27
   PubMed Web of Science ®Google Scholar
• Steffensen I, Faurschou P, Rista H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airways disease. Allergy 1995; 50: 657–663
   PubMed Web of Science ®Google Scholar
• Häcki MA, Hinz GW, Medici TC. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest 1997; 14: 165–174
   Web of Science ®Google Scholar
• Larsen JS, Hahn M, Ekholm B, Wick KA. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994; 31: 193–199
   PubMed Web of Science ®Google Scholar
• Labrune S, Chinet T, Huchon G. Inhaled therapy in asthma: metered-dose inhaler experience. Monaldi Arch Chest Dis 1994; 49: 254–257
   PubMedGoogle Scholar
• Vervloet D, Ekström T, Pela R, Gracia FD, Kopp C, Silvert BD, Quebe-Fehling E, Della Cioppa G, Di Benedetto G. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998; 92: 836–842
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–1688
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420–1425
   PubMed Web of Science ®Google Scholar
• Lötvall J, Lunde H, Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J 1998; 5: 91–94
   PubMedGoogle Scholar
• Brogden RN, Faulds D. Salmeterol xinofoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 895–912
   PubMed Web of Science ®Google Scholar
• Arvidsson P, Larsson S, Löfdahl C-G, Melander B, Svedmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168–1173
   PubMed Web of Science ®Google Scholar
• Kesten S, Chapman KR, Broder J, Cartier A, Hyland RH, Knight A, Malo JL, Mazza JA, Moote DW, Small P. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622–625
   PubMed Web of Science ®Google Scholar
• Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P. Com-parison between formoterol 12 µg b.i.d and on-demand salbutamol in moderate persistent asthma. Respir Med 2001; 94: 64–70
   Google Scholar
• Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000; 56: 363–370
   PubMed Web of Science ®Google Scholar